Accentia Biopharma (ABPI) Subsidiary, Biovest International (BVTI), Receives Positive Opinion for BiovaxID
More News related to ABPI
- Accentia Biopharmaceuticals (ABPI) Reports Q3 Loss of $0.25
- Accentia Biopharmaceuticals (ABPI) Agrees to $8.5M Private Placement to Fund SinuNase(TM) and Revimmune(TM) Strategies
- Unusual 11 Mid-Day Movers 6/11: ABPI, KMGB, FCN, AGU Higher; CENT, FED, SNIC, MTG Lower
- Accentia Biopharmaceuticals (ABPI) Announces SinuNase Fast-Tracked Pivotal Phase 3 Study in Chronic Sinusitis Shows Statistically Significant
- Pre-Open Movers 4/17: FUQI Intl (FUQI) Higher on Raised Guidance, Nokia (NOK) Lower on Results/Outlook
More News related to BVTI
- Mentor Capital Cancer Immunotherapy Index Improves at a 320% Annualized Rate for Quarter
- Unusual 11 Mid-Day Movers 6/11: ABPI, KMGB, FCN, AGU Higher; CENT, FED, SNIC, MTG Lower
- Accentia Biopharmaceuticals (ABPI) Subsidiary Receives Rare Disease Designation in Europe
- Accentia Biopharma (ABPI) Subsidiary, Biovest International (BVTI), Receives Positive Opinion for BiovaxID
- Accentia Biopharmaceuticals (ABPI) Subsidiary Biovest (BVTI) Receives FDA Fast Track Status For BiovaxID
More News related to FDA
- Top 10 News Items 11/23-11/27: Dubai Debt Fallout; Gold; GDP Revised Lower; Diedrich Coffee Bidding War
- Trading Radar for 11/30: Inergy Holdings (NRGP), Golar (GLNG), Omnivision (OVTI), Knightsbridge (VLCCF) Report
- Notable Mergers and Acquisitions of the Day for 11/27: F, S/IPCS, STAR/CSCO, HRAY
- Notable Analyst Rating Changes 11/27: TIF, QLTI Upgraded; FSNM, RGFC Downgraded
- Notable ETF Movers *Special Dubai World Edition* 11/27: UUP Higher; GAF, EEM, FXI, XLF Lower
Biovest International, Inc. (OTCBB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI), has received official notification from the Committee on Orphan Medical Products (COMP) of the European Medicines Agency that a positive opinion was made regarding the application for orphan medicinal product designation for BiovaxID the Company's autologous immunotherapy for the treatment of follicular lymphoma in the European Union (EU).
In its letter to Biovest, the COMP noted that while treatments for follicular lymphoma are currently available, "..justifications have been provided that autologous tumor-derived immunoglobulin idiotype coupled to keyhole limpet hemocyanin may be of significant benefit to those affected by the condition."
The positive opinion of the COMP has now been forwarded to the EU commission for final approval and publication in the community register.
Related Categories
FDAStocks Mentioned
+0.00
-0.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
